117 related articles for article (PubMed ID: 7635451)
21. Expression of keratinocyte growth factor receptor compared with that of epidermal growth factor receptor and erbB-2 in endometrial adenocarcinoma.
Visco V; Carico E; Marchese C; Torrisi MR; Frati L; Vecchione A; Muraro R
Int J Oncol; 1999 Sep; 15(3):431-5. PubMed ID: 10427121
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
23. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
Soovares P; Pasanen A; Bützow R; Lassus H
Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
[TBL] [Abstract][Full Text] [Related]
24. Endoglin (CD105) expression in endometrial carcinoma.
Saad RS; Jasnosz KM; Tung MY; Silverman JF
Int J Gynecol Pathol; 2003 Jul; 22(3):248-53. PubMed ID: 12819391
[TBL] [Abstract][Full Text] [Related]
25. Endometrioid endometrial carcinomas with microcystic, elongated, and fragmented (MELF) type of myoinvasion: role of immunohistochemistry in the detection of occult lymph node metastases and their clinical significance.
Espinosa I; Serrat N; Zannoni GF; Rovira R; D'Angelo E; Prat J
Hum Pathol; 2017 Dec; 70():6-13. PubMed ID: 28601659
[TBL] [Abstract][Full Text] [Related]
26. Preoperative cervical cytology in endometrial carcinoma and its clinicopathologic relevance.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H; Yamasaki F
Gynecol Oncol; 1999 Mar; 72(3):273-7. PubMed ID: 10053095
[TBL] [Abstract][Full Text] [Related]
27. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T
BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
Talvensaari-Mattila A; Santala M; Soini Y; Turpeenniemi-Hujanen T
Anticancer Res; 2005; 25(6B):4101-5. PubMed ID: 16309203
[TBL] [Abstract][Full Text] [Related]
29. p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections.
Nielsen AL; Nyholm HC
Am J Clin Pathol; 1994 Jul; 102(1):76-9. PubMed ID: 7913577
[TBL] [Abstract][Full Text] [Related]
30. Expressions and clinical significance of COX-2, VEGF-C, and EFGR in endometrial carcinoma.
Cai S; Zhang YX; Han K; Ding YQ
Arch Gynecol Obstet; 2017 Jul; 296(1):93-98. PubMed ID: 28474124
[TBL] [Abstract][Full Text] [Related]
31. Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer.
Pelletier MP; Trinh VQ; Stephenson P; Mes-Masson AM; Samouelian V; Provencher DM; Rahimi K
Hum Pathol; 2017 Apr; 62():33-39. PubMed ID: 27864117
[TBL] [Abstract][Full Text] [Related]
32. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.
Nazeer T; Ballouk F; Malfetano JH; Figge H; Ambros RA
Am J Obstet Gynecol; 1995 Dec; 173(6):1829-34. PubMed ID: 8610771
[TBL] [Abstract][Full Text] [Related]
33. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
[TBL] [Abstract][Full Text] [Related]
34. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
Stefansson IM; Salvesen HB; Immervoll H; Akslen LA
Histopathology; 2004 May; 44(5):472-9. PubMed ID: 15139995
[TBL] [Abstract][Full Text] [Related]
36. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
[TBL] [Abstract][Full Text] [Related]
37. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.
Bland AE; Stone R; Heuser C; Shu J; Jazaeri A; Shutter J; Atkins K; Rice L
Int J Gynecol Cancer; 2009 Feb; 19(2):261-5. PubMed ID: 19396006
[TBL] [Abstract][Full Text] [Related]
38. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract][Full Text] [Related]
40. Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma.
Lijun Z; Xin Z; Danhua S; Xiaoping L; Jianliu W; Huilan W; Lihui W
Int J Gynecol Cancer; 2012 Jun; 22(5):836-41. PubMed ID: 22617481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
